Regina joined Wellington Partners in spring 2010. She is a General Partner and represents the Wellington Partners funds on the Board of Middle Peak Medical, Ayoxxa, Sapiens and Atopix, and is an external director at GlaxoSmithKline's Respiratory TA Board. Since joining the industry in 2000, she has become an influential investor in the European venture capital industry, focusing on early-stage and growth deals in Life Sciences.
Until January 2010, Regina led the life sciences efforts of Atlas Venture in Europe, a leading transatlantic venture capital firm. As a Partner at Atlas Venture, she led numerous financing rounds and was the founding investor in Bicycle Therapeutics, Fibrex, F-star and Jenavalve. Regina served on several Boards, including the Board of U3 Pharma, which was acquired by Daiichi Sankyo Co. Ltd in 2008 and Novamed, which was acquired by SciClone in 2010.